Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$7.65 USD

7.65
825,715

-0.09 (-1.16%)

Updated Jun 7, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev

by Zacks Equity Research

Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.

F-star (FSTX), AstraZeneca Team Up for Novel STING Inhibitors

by Zacks Equity Research

F-star partners with AstraZeneca for its novel STING inhibitor compounds. Resultantly, F-star's shares rise 9.1%.

Kinjel Shah headshot

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)

by Kinjel Shah

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations

by Zacks Equity Research

Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.

Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral

by Zacks Equity Research

Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.

ChemoCentryx (CCXI) Files Amendment to NDA for Avacopan

by Zacks Equity Research

ChemoCentryx (CCXI) files an amendment to its NDA for avacopan for treatment of ANCA-associated vasculitis. The new PDUFA date is Oct 7. The filing constitutes a major amendment to the original NDA.

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.

Kinjel Shah headshot

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season

by Kinjel Shah

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

by Zacks Equity Research

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now

by Zacks Equity Research

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.

Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo

by Zacks Equity Research

Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer

Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag

by Zacks Equity Research

Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.

CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study

by Zacks Equity Research

CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.

Kinjel Shah headshot

3 Big Drugmakers Likely to be in Focus in Second Half of 2021

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.

Horizon (HZNP) Begins Phase II Study for Lupus Candidate

by Zacks Equity Research

Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.

BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism

by Zacks Equity Research

Biomarin Pharmaceutical (BMRN) receives positive recommendation from Europe's CHMP for vosoritide to treat achondroplasia in children.

Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.

J&J (JNJ)/Bayer Seek Nod for Xarelto for Blood Clots in Kids

by Zacks Equity Research

J&J (JNJ) and its partner Bayer seek approval of Xarelto as a treatment and prevention for venous thromboembolism in pediatric patients.

AstraZeneca (AZN) Rare Disorder Drug Koselugo Gets EU Nod

by Zacks Equity Research

AstraZeneca's (AZN) Koselugo becomes the first medicine approved in Europe for neurofibromatosis type 1 plexiform neurofibromas.

    Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

    by Zacks Equity Research

    Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.

    CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data

    by Zacks Equity Research

    CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.

    CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases

    by Zacks Equity Research

    CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

    Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20

    by Zacks Equity Research

    Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.